It is clear that several prostate cancers remain indolent whereas others develop into advanced forms. There is a need to improve patient management by identifying biomarkers for personalized treatment. We demonstrated that miR-15/miR-16 loss, miR-21 upregulation, and deregulation of their target genes represent a promising predictive signature of poor patient prognosis.
Molecular & cellular oncology. 2015 Dec 10*** epublish ***
Désirée Bonci, Ruggero De Maria
Department of Hematology, Oncology and Molecular Medicine, Instituto Superiore di Sanità, Rome, Italy; Scientific Directorate, Regina Elena National Cancer Institute, Rome, Italy., Scientific Directorate, Regina Elena National Cancer Institute , Rome, Italy.